Global Cardiology Science & Practice最新文献

{"title":"Unmasking cor triatriatum dexter in adult patients with atrial arrhythmia.","authors":"Abdul Hakim Almakadma, Diana Inshyna, Parkha Khan, Mohamed Sabra, Ramzi Ibrahim, Meena Farid, Umida Burkhanova, Davendra Mehta, Farzane Saeidifard, Hal L Chadow","doi":"10.21542/gcsp.2026.23","DOIUrl":"10.21542/gcsp.2026.23","url":null,"abstract":"<p><p>Cor triatriatum dexter is a rare congenital cardiac anomaly characterized by persistence of a membranous structure that divides the right atrium into two chambers. Although often asymptomatic, cor triatriatum dexter may present in adulthood with nonspecific symptoms and atrial arrhythmias, including atrial fibrillation and atrial flutter. We present a case series of four adult patients in whom cor triatriatum dexter was incidentally diagnosed during cardiac evaluation for diverse clinical presentations. Patients ranged in age from 51 to 75 years and presented with new-onset seizures, ischemic stroke evaluation, heart failure exacerbation, and recurrent atrial arrhythmias. In all cases, diagnosis was established using echocardiographic imaging, with transesophageal echocardiography providing definitive visualization when transthoracic studies were nondiagnostic. This series highlights the diagnostic challenges of cor triatriatum dexter in adults and suggests that the condition may be underrecognized. Furthermore, altered right atrial anatomy may be associated with atrial arrhythmia maintenance through structural and conduction alterations of the right atrium.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 3","pages":"e202623"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes with vutrisiran in transthyretin amyloidosis: a systematic review and meta-analysis of randomized trials.","authors":"Faizan Ahmed, Faseeh Haider, Ayesha Zulfiqar, Tooba Nihal, Maliha Khalid, Areej Dar, Saman Rauf, Noor Ul Ain Saleem, Hassan Farooq, Haris Bin Tahir, Ramsha Ali, Haider Hussain Shah, Swapnil Patel, Mohammad Hossain, Fawaz Alenezi","doi":"10.21542/gcsp.2026.25","DOIUrl":"10.21542/gcsp.2026.25","url":null,"abstract":"<p><p><b>Background:</b> Transthyretin amyloidosis (ATTR) is a progressive disease that causes a restrictive cardiomyopathy. Vutrisiran, a subcutaneous RNA interference (RNAi) therapy, is an approved treatment. This systematic review and meta-analysis evaluates its efficacy and safety with respect to transthyretin (TTR) reduction, functional capacity, quality of life, mortality, and adverse events. <b>Methods:</b> We identified 1,032 records, of which three randomized controlled trials-HELIOS-A, HELIOS-B, and a Phase 1 study-comprising 976 participants (508 vutrisiran; 468 comparator) met the inclusion criteria. Comparator participants received placebo, patisiran (an active reference comparator in HELIOS-A), or external placebo from the APOLLO trial. Outcomes assessed were TTR reduction, functional capacity, quality of life, mortality, and adverse events, pooled using random-effects models reporting mean differences and risk ratios. <b>Results:</b> Vutrisiran achieved a rapid, durable TTR reduction of up to 97% in healthy volunteers at the highest dose, and a sustained steady-state reduction in the HELIOS-A and HELIOS-B trials. QoL outcomes showed a protective effect of vutrisiran, with slowed deterioration in the intervention group. Functional outcomes (10-MWT, 6-MWT) suggested slower decline in mobility and functional capacity. Mortality showed a non-significant reduction (RR 0.51; <i>p</i> = 0.29; I² = 62%), with most deaths considered unrelated to treatment. The safety analysis showed fewer falls (RR 0.62; <i>p</i> = 0.001; I² = 0%) but no significant difference in overall adverse events (AEs) (RR 1.01; <i>p</i> = 0.76) or serious AEs (RR 0.82; <i>p</i> = 0.23). A sensitivity analysis supported the adverse-event findings. <b>Conclusions:</b> Vutrisiran consistently suppressed TTR and showed signals of benefit in quality of life, function, and mortality, though most of these outcomes did not reach statistical significance. It reduced fall risk without increasing adverse events, indicating a favourable safety profile. Larger, long-term RCTs are needed to confirm survival and functional benefits.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 3","pages":"e202625"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital education for cardiac care readiness among coronary heart disease patients in low- and middle-income countries: a scoping review.","authors":"Nuridah, Rosyidah Arafat, Andi Masyitha Irwan","doi":"10.21542/gcsp.2026.27","DOIUrl":"10.21542/gcsp.2026.27","url":null,"abstract":"<p><p><b>Introduction:</b> Coronary heart disease (CHD) is the leading cause of cardiovascular mortality worldwide, with the greatest burden concentrated in low- and middle-income countries (LMICs). Patient readiness-encompassing knowledge, self-efficacy, and self-care behaviour-is a critical determinant of post-discharge outcomes. Digital education interventions offer an innovative, resource-efficient approach to improving CHD patient readiness in LMICs; however, the available evidence has not been systematically mapped. <b>Methods:</b> This scoping review followed the Arksey and O'Malley framework and was reported in accordance with the PRISMA Extension for Scoping Reviews (PRISMA-ScR). A systematic search was conducted across four databases-PubMed, ScienceDirect, Wiley Online Library, and the Cochrane Library-for publications from 2019 to 2026. The most recent searches were run on 1 March 2026 and supplemented by manual screening of reference lists. <b>Results:</b> Eleven studies were included, comprising 7 full RCTs (63.6%), 1 pilot RCT (9.1%), 2 RCT protocols (18.2%), and 1 feasibility study (9.1%). Geographic distribution included China (<i>n</i> = 4; 36.4%), Iran (<i>n</i> = 4; 36.4%), Colombia (<i>n</i> = 1; 9.1%), Tunisia (<i>n</i> = 1; 9.1%), and Brazil (<i>n</i> = 1; 9.1%). The most frequently used primary delivery platforms were mobile applications/smartphones (<i>n</i> = 3; 27.3%), WeChat (<i>n</i> = 2; 18.2%), WhatsApp (<i>n</i> = 2; 18.2%), Web-based/online platforms (<i>n</i> = 2; 18.2%), augmented reality (<i>n</i> = 1; 9.1%), and digital multimedia (<i>n</i> = 1; 9.1%). The most commonly measured outcomes were self-efficacy (<i>n</i> = 4; 36.4%), quality of life (<i>n</i> = 3; 27.3%), disease knowledge/illness perception (<i>n</i> = 3; 27.3%), medication adherence/self-management (<i>n</i> = 3; 27.3%), and clinical events (<i>n</i> = 1; 9.1%). Discharge readiness was not measured as a primary outcome in any included study. <b>Conclusion:</b> Digital education interventions show promising potential for improving the components of CHD patient readiness in LMICs; however, the evidence remains concentrated in China and Iran. Research specifically targeting discharge readiness with validated instruments is urgently needed across diverse LMIC settings, particularly in Southeast Asia, sub-Saharan Africa, and Latin America.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 3","pages":"e202627"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant effect of high altitude and thrombophilia on multi-organ thrombosis.","authors":"Feridoun Sabzi, Reza Faraji, Fariba Shokri, Abbas Ghaysouri, Abbas Maleki, Taha Rashidi","doi":"10.21542/gcsp.2026.22","DOIUrl":"10.21542/gcsp.2026.22","url":null,"abstract":"<p><p>We report the case of a 33-year-old male mountaineer, presenting with chest pain, severe headache, dyspnea, and lower extremity edema, on his first expedition to Paraw mountain located in Kermanshah Province. His condition involved a complex thrombotic presentation, including both venous and arterial events, such as a myocardial infarction due to stenosis of the left main coronary artery, which we believe to be a coincidental pathology. His neurological symptom includes headache, vomiting, and slight drowsiness associated with chest pain, which were evaluated alongside confirmatory testing for protein C-S deficiency. Physical examination revealed right lower extremity edema, respiratory distress (RR = 34), and mid-drowsiness. Chest X ray showed lung congestion. A history of recurrent thrombophlebitis, along with the current myocardial infarction, raised suspicion of a thrombophilic state. The final diagnosis of these complications was confirmed to have protein C-S deficiency based on laboratory tests performed during the acute phase. However, the hereditary nature of this deficiency remains unconfirmed as no genetic testing or family screening was undertaken. The patient underwent coronary artery bypass grafting of left anterior descending artery (LAD) and LCX associated with anticoagulant therapy, and his neurologic sign and symptom and lower extremity deep vein thrombosis recovered uneventfully.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 3","pages":"e202622"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease.","authors":"Israa O Kashmoola, Shatha H Mohammad, Mohammad H Alsaaty","doi":"10.21542/gcsp.2026.20","DOIUrl":"10.21542/gcsp.2026.20","url":null,"abstract":"<p><p>Oxidative stress and adipokine imbalance are important contributors to the pathogenesis of diabetic cardiovascular disease. The nuclear factor erythroid 2-related factor 2 (Nrf2) regulates antioxidant defense, while adipokines link metabolism and inflammation. Incretin-based therapies and PPARγ agonists may join on these pathways to provide cardiovascular protection beyond glycemic control. This review aims to investigate the current evidence on how incretin-based agents and PPARγ agonists regulate the adipokine-Nrf2 axis and their impact on cardiovascular outcomes in diabetes. A literature search was performed using PubMed, Google Scholar and Scopus to include reviews, experimental, clinical, and translational studies published in English until November 2025. Evidence indicates that incretin-based agents and PPARγ agonists synergistically activate Nrf2 and inhibit NF-kB signaling, leading to improved oxidative status and favorable adipokine levels. Increased adiponectin and omentin, and suppressed resistin, leptin and TNF-α contribute to reduced inflammation and enhanced vascular and myocardial protection. Collectively, combined activation of incretin and PPARγ pathways modulates the adipokine-Nrf2 axis, offering joined antioxidant and anti-inflammatory benefits that may reduce diabetic cardiovascular risk.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 3","pages":"e202620"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting short-term blood pressure trajectories using lifestyle and behavioural factors: a prospective cohort study.","authors":"Merugu Sudhakar, Pradeep Dayanand, Sandeep Dayanand, Jasmin Martinez, Tridev Adak","doi":"10.21542/gcsp.2026.24","DOIUrl":"10.21542/gcsp.2026.24","url":null,"abstract":"<p><p><b>Background:</b> Hypertension is a major contributor to cardiovascular morbidity and mortality. While lifestyle modification is central to prevention, evidence on short-term blood pressure (BP) dynamics in relation to behavioural factors remains limited. <b>Objective:</b> To evaluate the influence of diet, physical activity, and psychological stress on systolic blood pressure (SBP) trajectories and to develop a regression-based model for short-term BP prediction. <b>Methods:</b> In this 12-week prospective cohort study, 75 adults attending a preventive cardiology clinic were followed, with BP measured at baseline, 6 weeks, and 12 weeks using validated oscillometric methods. Lifestyle and behavioural factors were assessed using the Food Frequency Questionnaire (sodium intake and DASH adherence), IPAQ-SF (physical activity), and PSS-10 (stress). Linear mixed-effects regression identified predictors of SBP change, and Elastic Net regression predicted 12-week SBP. <b>Results:</b> Sixty-seven participants (mean age 44.6 ± 10.8 years; 52.2% male) completed follow-up. Mean SBP declined from 134.2 ± 12.6 to 131.4 ± 11.5 mmHg. Higher physical activity and DASH adherence were associated with SBP reduction, whereas higher sodium intake and stress predicted SBP elevation (all <i>p</i> < 0.05). The Elastic Net model demonstrated strong predictive performance (<i>R</i> ² = 0.78; RMSE = 5.9 mmHg). Physical activity had a stronger effect in participants <45 years, and stress amplified sodium-related SBP increases. <b>Conclusions:</b> Short-term SBP trajectories are strongly influenced by modifiable behavioural factors. Predictive models based on lifestyle data may support early risk stratification and personalized hypertension prevention.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 3","pages":"e202624"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Catheter ablation versus no ablation for atrial fibrillation in cardiac amyloidosis: a propensity-matched cohort study.","authors":"Joud Fahed, Mohammad Hamza, Azka Naeem, Asad Ur Rab, Muhammad Hashim Khan, Mohammad Ali Sheffeh, Jawad Basit, Salem Assiri, M Chadi Alraies","doi":"10.21542/gcsp.2026.26","DOIUrl":"10.21542/gcsp.2026.26","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) is extremely common in cardiac amyloidosis (CA) due to amyloid infiltration and atrial electrical remodeling. We aim to compare ablation outcomes versus no-ablation in patients taking anti-arrhythmic drugs (AAD) in CA-associated AF.</p><p><strong>Methods: </strong>Using TriNetX database (2019-2025), 5,562 patients with CA and AF were identified and divided into two groups: catheter ablation plus AADs (<i>n</i> = 893) versus medical therapy alone (<i>n</i> = 4,669). Baseline characteristics were adjusted and 1:1 propensity score matching was performed to account for baseline differences. Primary composite outcome included all-cause mortality, ischemic strokes, bleeding and subsequent myocardial infarction.</p><p><strong>Results: </strong>870 patients were included in each cohort. At 12-month follow-up, catheter ablation was associated with a significantly lower risk of the composite outcome (8.3% vs 13.2%; HR 0.591, 95% CI [0.418-0.834], <i>p</i> = 0.002), and reduced all-cause mortality. There were no significant differences in all-cause hospitalization, emergency department visits, new-onset heart failure, atrioventricular block, or cardiac arrest. Repeat ablation or cardioversion, and subsequent pacemaker or ICD implantation were more frequent in the ablation group.</p><p><strong>Conclusion: </strong>Catheter ablation was associated with improved short-term outcomes despite higher arrhythmia recurrence. Ablation may be considered in carefully selected patients, particularly those with earlier-stage disease or significant symptoms.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 3","pages":"e202626"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Anxiety-AFib connection: a systematic review of mental health and arrhythmia interactions.","authors":"Sania Simon, Kavach J Josh, Vilina H Gangolli, Irene Sairah Paul, Kedargouda S Patil, Aneesh Nelivigi, Kevin Thomas Mathew, Amna Shamim, Lakshmi Priya Kopudu Sridharbabu","doi":"10.21542/gcsp.2026.28","DOIUrl":"10.21542/gcsp.2026.28","url":null,"abstract":"<p><p><b>Background:</b> Atrial fibrillation is the most common cardiac arrhythmia, which has effects that goes beyond the heart, often affecting mental health. Over the years, increasing evidence has highlighted a bidirectional connection between anxiety and atrial fibrillation. However, the connection between the two in clinical practice is vague. <b>Objective:</b> This systematic review aims to investigate the relationship between anxiety and atrial fibrillation, including how anxiety might contribute to the onset and relapse of atrial fibrillation, how it may impact the treatment outcomes and its effects on the patient's overall quality of life. <b>Methods:</b> We conducted an extensive search of PubMed, Scopus, Embase, and Cochrane to systematically identify studies between 2020 and 2025. Adult patients with atrial fibrillation diagnosis who were assessed for anxiety were included using validated scales. A total of 84 articles met the inclusion criteria, with data extracted on anxiety measures, features of atrial fibrillation, clinical impact, and treatment effects. <b>Results:</b> Among the reviewed studies, anxiety was both prevalent in AF patients and significantly associated with poorer clinical outcomes across the majority of included studies, though the strength and nature of associations varied across study designs and populations. Patients with higher levels of anxiety had a higher probability of recurrent atrial fibrillation, increased symptom burden, and lower health-related quality of life. Anxiety also influenced treatment outcomes and adherence, particularly regarding anticoagulation and ablation therapy. Notably, several interventions including catheter ablation and structured patient education were associated with reductions in anxiety and improvements in outcomes. Importantly, one Mendelian randomisation study found no causal relationship between anxiety and AF, while depression and panic disorder showed causal associations, underscoring the need for cautious interpretation of observational findings. <b>Conclusion:</b> Anxiety and atrial fibrillation appear to share a complex, predominantly bidirectional association. While most observational studies support a link between anxiety and worse AF-related outcomes, evidence from Mendelian randomisation does not confirm a causal role for anxiety in AF onset, suggesting that residual confounding may partly account for observational associations. Addressing mental health in AF care is nonetheless clinically important. Incorporating psychological assessment and support into AF management may reduce symptom burden and improve treatment adherence and quality of life. Further research, particularly longitudinal interventional studies using standardised instruments, is required to guide more comprehensive, patient-centred care.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 3","pages":"e202628"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complicated third sternotomy for left ventricular outflow tract obstruction secondary to mitral valve prosthesis strut.","authors":"Rishab Agarwal, AlleaBelle Bradshaw, Michelle Carvajal, Jennifer S Lawton","doi":"10.21542/gcsp.2026.13","DOIUrl":"10.21542/gcsp.2026.13","url":null,"abstract":"<p><p><b>Introduction</b>: LVOT obstruction after surgical bioprosthetic MVP placement is uncommon and the influence of the MVP strut width has seldom been examined. <b>Case presentation</b>: A 74-year-old female presented with palpitations, chest pain, and shortness of breath. She had MVR with 31-mm bioprosthetic valve 2 years prior. TEE confirmed LVOT obstruction secondary to a MVP strut, causing a peak gradient of 55 mmHg. The redo operation was complicated by iatrogenic Type A aortic dissection. The patient was immediately cooled for DHCA with RCP and ascending aortic replacement was performed. MVR was then performed with a prosthesis with narrower strut width. Recovery after surgery was uneventful and post-bypass TEE confirmed absence of LVOT obstruction (gradient of 4 mmHg). <b>Discussion</b>: This case is of interest for two reasons. Primarily, the overall profile of the valve, including the width of the struts may play a significant role in the development of LVOT obstruction after MVR. Additionally, the patient had an ITAAD requiring prompt and thoughtful management. <b>Conclusions</b>: This case underscores the importance of evaluating MVP profile in relation to patient anatomy. Furthermore, intraoperative Type A aortic dissection is a rare but lethal phenomenon requiring swift decision-making and technical ability, and both are important considerations for trainees.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 2","pages":"e202613"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13197850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An <i>in silico</i> bioinformatics framework for prioritizing candidate genes in the coronary no-reflow phenomenon.","authors":"Fadhlan Abdur Rahman, Suryono Suryono, Aditha Satria Maulana, Pipiet Wulandari","doi":"10.21542/gcsp.2026.14","DOIUrl":"10.21542/gcsp.2026.14","url":null,"abstract":"<p><p><b>Background:</b> The coronary no-reflow phenomenon remains a major obstacle to optimal outcomes after primary percutaneous coronary intervention. Its mechanisms are multifactorial and not fully clarified, with genetic components increasingly recognized as important contributors. This study aims to identify key genes, characterize their biological functions, and explore <i>in silico</i>-based therapeutic options targeting genes implicated in this condition. <b>Methods:</b>Genes related to the coronary no-reflow phenomenon were retrieved from the GeneCards database. A protein-protein interaction network was constructed using STRING, and top-ranked genes were identified via the maximal cliques centrality and maximum neighborhood component algorithms in Cytoscape. Gene ontology enrichment analysis was performed using WebGestaltR. Three-dimensional protein structures were generated with SWISS-Model and validated using ERRAT and PROCHECK. <b>Results:</b> Seventy-nine genes with significant relevance were identified. Network analysis yielded 55 nodes, from which eight hub genes were identified: IL6, TNF, ICAM1, MPO, ALB, MMP9, CXCL8, and CRP. Enrichment analysis highlighted blood vessel diameter maintenance and coagulation as key biological processes, with antioxidant activity as the leading molecular function. MPO, CRP, CXCL8, and ALB demonstrated favorable structural characteristics, supporting their prioritization. <b>Conclusion:</b> MPO, CRP, CXCL8, and ALB are central genes in the coronary no-reflow phenomenon and warrant further experimental validation for therapeutic development.</p>","PeriodicalId":12669,"journal":{"name":"Global Cardiology Science & Practice","volume":"2026 2","pages":"e202614"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13197852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}